Table 4. GSEA results of involution-specific signatures in IBC versus non-IBC in the merged 3 breast cancer data sets.
| Gene Signature | Merged 3 breast cancer data sets IBC = 137 and non-IBC = 251 # Genes = 12064 |
|||||
|---|---|---|---|---|---|---|
| Enriched in IBC versus non-IBC | Size | ES | NES | Nominal p-value | FDR q-value | |
| Involution specific signatures developed through STEM clustering using data from Clarkson et al. 2004 | ||||||
| Inv1 | IBC | 205 | 0.29 | 0.88 | 0.584 | 0.869 |
| Inv2 | IBC | 100 | 0.13 | 0.52 | 0.97 | 0.988 |
| Inv3 | IBC | 57 | 0.25 | 0.81 | 0.807 | 0.902 |
| Inv4 | IBC | 33 | 0.32 | 0.94 | 0.541 | 0.873 |
| Inv5 | IBC | 30 | 0.51 | 1.47 | 0.03 | 0.392 |
| Inv6 | IBC | 62 | 0.42 | 1.47 | 0.021 | 0.204 |
| Inv7 | IBC | 36 | 0.26 | 0.75 | 0.867 | 0.896 |
| Inv8 | Non-IBC | 24 | -0.3 | -0.92 | 0.573 | 0.541 |
| Inv9 | IBC | 33 | 0.54 | 1.22 | 0.279 | 0.407 |
| Inv10 | IBC | 21 | 0.43 | 1.34 | 0.122 | 0.298 |
| Involution specific signatures reported in Stein et al. 2009 | ||||||
| S.C1 | IBC | 182 | 0.4 | 1.08 | 0.379 | 0.614 |
| S.C2 | Non-IBC | 205 | -0.25 | -0.77 | 0.735 | 0.902 |
| S.C3 | Non-IBC | 252 | -0.19 | -0.72 | 0.783 | 0.849 |
| S.C4 | Non-IBC | 258 | -0.21 | -0.89 | 0.568 | 1 |
| S.C5.I3VL7 | IBC | 117 | 0.29 | 1.1 | 0.315 | 0.818 |
| S.C6 | Non-IBC | 100 | -0.26 | -0.99 | 0.48 | 1 |
| S.C7 | IBC | 225 | 0.28 | 1.13 | 0.26 | 1 |
| S.C8 | Non-IBC | 153 | -0.22 | -0.88 | 0.717 | 0.835 |
| S.C9 | Non-IBC | 66 | -0.37 | -1.21 | 0.189 | 0.847 |
| S.I1VL7 | IBC | 495 | 0.19 | 0.83 | 0.717 | 0.639 |
| S.I2VL7 | IBC | 612 | 0.21 | 0.87 | 0.671 | 0.798 |
| S.I3VL7 | IBC | 648 | 0.21 | 0.84 | 0.694 | 0.729 |
| S.I4VL7 | IBC | 894 | 0.23 | 0.9 | 0.591 | 0.882 |